Quality assurance in human papillomavirus testing for primary cervical screening.
Cervical Cancer
Cervix Uteri
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
3
5
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
epublish
Résumé
The recommendation for cervical screening is that it should be based on human papillomavirus (HPV) molecular testing. For all screening programs, attention to quality assurance is required to fully realize the benefits. Internationally recognized quality assurance recommendations for HPV-based screening are needed that are ideally applicable for a variety of settings, including in low- and middle-income countries. We summarize the main points of quality assurance for HPV screening, with a focus on the selection, implementation, and use of an HPV screening test, quality assurance systems (including internal quality control and external quality assessment), and staff competence. While we recognize that it might not be possible to fulfill all points in all settings, an awareness of the issues is essential.
Identifiants
pubmed: 36914171
pii: ijgc-2022-004197
doi: 10.1136/ijgc-2022-004197
pmc: PMC10176393
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
802-811Informations de copyright
© IGCS and ESGO 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Chem Lab Med. 2017 Feb 1;55(2):195-202
pubmed: 27816947
Pathology. 2018 Oct;50(6):659-664
pubmed: 30139535
J Clin Virol. 2021 Apr;137:104756
pubmed: 33662921
N Engl J Med. 2009 Apr 2;360(14):1385-94
pubmed: 19339719
J Med Biochem. 2017 Jul 14;36(3):231-237
pubmed: 30568539
J Clin Virol. 2016 Mar;76 Suppl 1:S22-S28
pubmed: 26669512
BMC Infect Dis. 2016 Nov 24;16(1):698
pubmed: 27881082
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
J Clin Virol. 2016 Mar;76 Suppl 1:S14-S21
pubmed: 26522865
Vaccine. 2006 Aug 31;24 Suppl 3:S3/193-200
pubmed: 16950007
Clin Microbiol Infect. 2021 Aug;27(8):1083-1095
pubmed: 33975008
Clin Microbiol Infect. 2020 Sep;26(9):1144-1150
pubmed: 32247892
Methods Mol Biol. 2015;1247:77-105
pubmed: 25399089
Int J Cancer. 2021 Dec 15;149(12):2083-2090
pubmed: 34418082
Cytopathology. 2019 May;30(3):273-280
pubmed: 30657615
J Clin Microbiol. 2016 Sep;54(9):2337-42
pubmed: 27385707
Int J Cancer. 2009 Feb 1;124(3):516-20
pubmed: 18973271
Vaccine. 2009 Jan 14;27(3):337-47
pubmed: 19007840
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969